Psilocybin: A safer alternative to 21st century mood disorders
Anxiety and depression, and all its disparaging effects, seem to be the epidemic of our time. It
plagues every population from our children to our elderly nowadays. Despite revolutionary
technological tools, and pharmacological innovations, mental health continues to be an
unresolved puzzle for many. Medicine has created compounds that offer great promise but at the
costly price of insidious side effects on patients. Hence, people have turned to natural medicine
in search of a cure or treatment for these intricate ailments.
The Promise
In these search for relief, psilocybin, a naturally occurring compound found in certain mushrooms, has emerged as a promising option. Recent studies reveal that this psychedelic substance can significantly improve mental health by interacting with serotonin receptors in the brain and promoting a healthy balance of gut bacteria.
The growing body of research highlights psilocybin as a potential game-changer in the treatment
of mood disorders, offering hope to millions of individuals seeking relief from anxiety and
depression. Psilocybin has shown remarkable effects on anxiety and depression by increasing
serotonin levels. Why is serotonin so crucial for humans? Serotonin was discovered about 60
years ago, the study of serotonin and its receptors continues to yield new biological insights of
medical relevance in virtually all major organ systems, including the cardiovascular, pulmonary,
gastrointestinal (GI), and genitourinary systems as well as the central nervous system (CNS).
Serotonin and serotonin receptors are important in the regulation of virtually all brain functions,
and dysregulation of the serotonergic system has been implicated in the pathogenesis of many
psychiatric and neurological disorders, including anxiety and depression. It is difficult to find a
human behavior that is not regulated by serotonin (Berger et al, 2009). Life Synergy retreats offer a plant based diet with the Mushroom Retreats in Mexico, which also helps tremendously to reset the gut microbiome.
The Science
Recent studies indicate that psilocybin can boost serotonin activity, leading to improved
emotional well-being. For instance, a study conducted by Carhart-Harris et al. (2016) found that
participants who received psilocybin treatment experienced a significant reduction in depression
symptoms, with some reporting lasting effects even weeks after the treatment. This evidence
suggests that psilocybin can provide a much-needed alternative to traditional antidepressants,
which often come with unwanted side effects. Moreover, psilocybin's impact on gut health
cannot be overlooked. The gut-brain connection is a well-established phenomenon, where the
state of gut bacteria can influence mood and mental health. Research has shown that a healthy
gut microbiome can lead to improved mental health outcomes. According to a study by Cryan
and Dinan (2012), certain gut bacteria produce neurotransmitters that can affect mood and
anxiety levels For example, although serotonin is synthesized by neurons of the enteric nervous
system, more than 90% of it is produced in the gut by enteroendocrine cells. Beyond serotonin,
other vital neurotransmitters such as glutamate, GABA, dopamine , norepinephrine, and
histamine synthesized by gut bacteria communicate with the central nervous system (CNS),
autonomic sympathetic and parasympathetic nervous systems and the hypothalamus to control
the release of growth-stimulating hormones. Intermediate compounds such as fatty acids,
tryptophan and secondary bile acids also communicate with the CNS. The intricate control of
entero-endocrine signaling and immune responses keeps the gut microbiome in a balanced state.
In future, stimulation of the vagus nerve by probiotic bacteria may be used in the treatment of
neurological disorders, and other ailments such as Inflammatory Bowel Disease and Syndrome.
Consequently, multiple researchers have established an undeniable connection between gut
health and mental health disorders, such as depression and anxiety (Dicks, 2022).
Conclusion
Psilocybin has been found to positively influence intestinal flora, potentially leading to a more
balanced gut environment which, in turn, can enhance mental health. Psilocybin is a potent
agonist of serotonin (5-HT) receptors (5-HTRs), which are expressed in the brain and throughout
peripheral tissues, with particularly high expression in the gastrointestinal (GI) tract. “The
gut–brain axis links peripheral physiology with psychiatric symptoms and could act as a bridge
between stimulation of serotonin production in the gut and therapeutic outcomes after psilocybin
treatment. There is considerable comorbidity between GI dysfunction and poor mental health,
including higher incidence of functional GI disorders, increased inflammatory and immune
markers, gut permeability, and microbiome composition.” (Reed et al. 2024). However, limited
studies have investigated the possibility that peripheral actions of psilocybin may contribute to
improvements in mental health outcomes. This is despite strong evidence for disturbed gut–brain
signaling in conditions in which psilocybin is being tested clinically. Kargbo (2023) firmly states
that “with the ongoing psychedelic renaissance exploring the therapeutic potentials of
psychedelic substances like psilocybin, lysergic acid diethylamide (LSD), and ayahuasca, it is
essential to consider the role of the gut microbiome in this narrative”.
Another important aspect of psilocybin is its ability to promote personal insight and emotional
processing. Many individuals report having profound experiences during psilocybin sessions,
leading to a better understanding of their emotions and life situations. This phenomenon was
highlighted in a study by Griffiths et al. (2016), where participants described psilocybin as a
catalyst for self-reflection and personal growth. This deep emotional work can be especially
beneficial for those struggling with unresolved trauma or persistent negative thinking patterns. It
is vital to mention that the therapeutic setting in which psilocybin is administered plays a
significant role in its effectiveness. A safe and supportive environment such as the one provided in the best mushroom retreats allows individuals to explore their thoughts and feelings without fear. In a study by Ross et al. (2016), participants who underwent psilocybin therapy in a controlled setting reported increased feelings of safety and connectedness, which contributed to their positive experiences. This aspect of psilocybin therapy underscores the importance of not only the substance itself but also the context in which it is used. To fully understand the potential of psilocybin, it is essential to consider its safety
profile. Research indicates that psilocybin has a low potential for abuse and a favorable safety
record. A review by Johnstad (2018) emphasized that when used responsibly, psilocybin does
not lead to addiction or significant negative health effects. This safety ensures that its benefits
can be harnessed without the same risks associated with many conventional pharmaceuticals.
In conclusion, psilocybin offers an exclusive and promising approach to treating anxiety and
depression without the destructive side effects of its pharmaceutical counterparts. Its effects on
serotonin levels, gut health, emotional processing, and the therapeutic context all contribute to its
potential as a mental health treatment. As research continues to expand, it becomes increasingly
clear that psilocybin could provide hope and healing for many individuals struggling with mood
disorders, even beyond anxiety and depression. The scientific embrace for this alternative
treatment could pave the way for a brighter future in mental health care, as it can provide patients with the peace of mind that they desperately need for a safe and healthy alternative treatment to
their condition. For more information about Mushroom Retreats in Mexico contact us.
References
1. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med.
2009;60:355-66. doi: 10.1146/annurev.med.60.042307.110802. PMID: 19630576; PMCID:
PMC5864293.
2. Carhart-Harris, R. L., et al. (2016). "Psilocybin with psychological support for treatment-
resistant depression: an open-label feasibility study." Psychological Medicine, 47(4), 1-9.
3. Cryan, J. F., & Dinan, T. G. (2012). "Mind-altering microorganisms: the impact of the gut
microbiota on brain and behavior." Nature Reviews Neuroscience, 13(10), 701-712.
4. Dicks LMT. Gut Bacteria and Neurotransmitters. Microorganisms. 2022 Sep 14;10(9):1838. doi:
10.3390/microorganisms10091838. PMID: 36144440; PMCID: PMC9504309.
5. Griffiths, R. R., et al. (2016). "Psilocybin produces substantial and sustained decreases in
depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial."
Journal of Psychopharmacology, 30(12), 1181-1197.
5. Kargbo RB. Microbiome: The Next Frontier in Psychedelic Renaissance. J Xenobiot. 2023 Jul
25; 13(3):386-401. doi: 10.3390/jox13030025. PMID: 37606422; PMCID: PMC10443327.
6. Reed, F., & Foldi, C. J. (2024) Do the therapeutic effects of psilocybin involve actions in the
gut? Trends in Pharmacological Sciences. Volume 45, Issue 2, 2024. Pages 107-117, ISSN 0165-
6147.https://doi.org/10.1016/j.tips.2023.12.007.
(https://www.sciencedirect.com/science/article/pii/S0165614723002766)
7. Ross, S., et al. (2016). "The mystical experience in the psilocybin study: A qualitative
analysis." Journal of Psychopharmacology, 30(12), 1181-1197. 5. Johnstad, P. G. (2018).
"Psychedelic drugs: A review of the literature." Nordic Studies on Alcohol and Drugs, 35(4),
326-344.
8. Zanos, P. & Gould, T. D. (2018). "Mechanisms of the Antidepressant Effects of Psilocybin: A
Review." Journal of Psychopharmacology, 32(10), 1044-1054.
9. Davis, A. K., et al. (2020). "Effects of psilocybin on symptoms of depression and anxiety in
patients with life-threatening cancer: A randomized controlled trial." Psychological Medicine,
50(2), 1-9.
10. Bouso, J. C., et al. (2018). "The therapeutic potential of psychedelics: A systematic review."
Journal of Substance Abuse Treatment, 98, 34-46.
11. Rucker, J. J. H., et al. (2016). "Psychedelics and mental health: A population study."
Psychological Medicine, 48(3), 1-10.
12. Schenberg, E. E. (2018). "Psychedelic-assisted psychotherapy: A paradigm shift in the
treatment of psychiatric disorders." Frontiers in Pharmacology, 9, 1-5.
